Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Rociletinib: Phase I/II data

December 8, 2014 8:00 AM UTC

Data from 27 evaluable NSCLC patients with the T790M EGFR resistance mutation in a Phase I/II trial showed that twice-daily 500 and 625 mg oral rociletinib led to an ORR of 67%, a disease control rate...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article